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Abstract
Psoriasis is a chronic inflammatory immune-mediated disorder affecting the skin and other organs 
including joints. Over 1,300 transcripts are altered in psoriatic involved skin compared to normal 
skin. However to our knowledge global epigenetic profiling of psoriatic skin is previously 
unreported. Here we describe a genome-wide study of altered CpG methylation in psoriatic skin. 
We determined the methylation levels at 27,578 CpG sites in skin samples from individuals with 
psoriasis (12 involved, 8 uninvolved) and 10 unaffected individuals. CpG methylation of involved 
skin differed from normal skin at 1,108 sites. Twelve mapped to the epidermal differentiation 
complex, upstream or within genes that are highly up-regulated in psoriasis. Hierarchical 
clustering of 50 of the top differentially methylated (DM) sites separated psoriatic from normal 
skin samples. CpG sites where methylation was correlated with gene expression are reported. Sites 
with inverse correlations between methylation and nearby gene expression include those of 
KYNU, OAS2, S100A12, and SERPINB3, whose strong transcriptional up-regulation are 
important discriminators of psoriasis. We observed intrinsic epigenetic differences in uninvolved 
skin. Pyrosequencing of bisulfite-treated DNA from skin biopsies at three DM loci confirmed 
earlier findings and revealed reversion of methylation levels towards the non-psoriatic state after 
one month of anti-TNF-α therapy.
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Introduction
Psoriasis is a chronic, relapsing inflammatory skin disease affecting approximately 2% of 
the U.S. population and 125 million people worldwide (Bowcock and Krueger, 2005; 
Gudjonsson et al., 2010; Suarez-Farinas et al., 2010). It is a lifelong disease presenting 
predominantly before the age of 40 with spontaneous remissions infrequent. Flares can be 
exacerbated by stress, infection, medications, or other environmental triggers (Langley et 
al., 2005). In psoriasis, immune cell activation and altered epidermal differentiation are key 
pathogenic events (Lew et al., 2004; Zaba et al., 2009) and these are correlated with major 
changes in the transcriptome (Bowcock et al., 2001; Gudjonsson et al., 2010; Mee et al., 
2007; Nomura et al., 2003; Quekenborn-Trinquet et al., 2005; Suarez-Farinas et al., 2010; 
Zhou et al., 2003).
Epigenetic alterations, such as DNA methylation and histone modification are correlated 
with gene expression changes (Champagne and Curley, 2009; Reik, 2007; Shi and Wu, 
2009; Wilson et al., 2009). Such alterations may be part of normal developmental or 
differentiation processes but can also be triggered by environmental factors (Eckhardt et al., 
2006; Morgan et al., 2005; Santos and Dean, 2004; Suter and Aagaard-Tillery, 2009; Weber 
et al., 2005). In mammals, DNA methylation commonly occurs at CpG dinucleotides 
(Bestor and Coxon, 1993). Approximately 70-80% of the CpG dinucleotides in the human 
genome are methylated, predominately in areas harboring repetitive sequences (Bird, 2002). 
However, regions rich in CpGs, termed CpG islands (CGIs), are also found in promoters of 
more than 70% of annotated genes (Bird et al., 1985; Saxonov et al., 2006). Approximately 
half of CGIs are associated with annotated gene transcription start sites (Bird, 2002), while 
others can have discrete sets of CpG sites within their promoters. The methylation of these 
sites has direct effects on transcriptional levels, where methylation levels typically 
demonstrate an inverse correlation with expression level (Bell et al., 2011).
There have been only a few studies of epigenetic alterations in diseased tissue. Many of 
these have involved cancerous tissue where the methylation status of tumor genomes are 
compared to matched normal tissue (Hu et al., 2005; Irizarry et al., 2009; Koga et al., 2009; 
Ordway et al., 2006). Studies of methylation changes in the diseased tissues of patients with 
complex diseases, including those leading to autoimmunity, are limited since diseased tissue 
is often difficult to access. A study on epigenetic changes in the blood of systemic lupus 
erythematosus patients revealed altered methylation of several genes contributing to T-cell 
autoreactivity, B-cell overstimulation and macrophage killing (Strickland and Richardson, 
2008). Psoriasis has an advantage over many autoimmune diseases due to the accessibility 
of its main target organ: the skin. There have been a few reports of altered methylation 
within promoters of single genes in diseased skin. One example is the SHP-1 (PTPN6) 
promoter which is reported to be demethylated in psoriatic skin but not in skin from atopic 
dermatitis (AD) patients or healthy controls (Ruchusatsawat et al., 2006). However, 
genome-wide studies of methylation changes in psoriasis to our knowledge have not been 
previously described.
Here we describe global changes of methylation in involved psoriatic skin (PP) versus 
uninvolved psoriatic (PN) and normal (NN) skin. This was performed by querying 27,578 
Roberson et al. Page 2
J Invest Dermatol. Author manuscript; available in PMC 2013 February 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
CpG sites with Illumina bead arrays with DNA derived from samples of each skin type. 
Many differences between PP versus NN skin were seen. Hierarchical clustering of 50 of the 
top differentially methylated sites demonstrated excellent power for differentiating PP 
versus NN skin. We also identified a subset of CpG sites where methylation was correlated 
with gene expression. Intermediate methylation at differentially methylated CpG sites was 
seen in PN skin, suggesting inherent epigenetic differences. Querying a subset of 
differentially methylated (DM) sites with an independent approach (pyrosequencing of 
bisulfite-treated DNA) confirmed the DM detected with the Illumina bead arrays, and also 
demonstrated that anti-TNF-α treatment in responders partially restores normal CpG 
methylation status at these loci.
Results
Differential CpG site methylation in psoriatic skin
We used the high throughput genome-wide bead-array (Infinium HumanMethylation27 
Beadchip, Illumina, Inc., USA) to obtain a global, quantitative measure of the methylation 
status of CpG sites in PP, PN and NN skin (GSE31835). The array spanned 27,578 CpG loci 
selected from more than 14,000 genes, including more than 1,000 cancer-related genes and 
the promoter regions of 110 miRNAs. The vast majority of assayed CpG sites were located 
in the promoter regions of their cognate genes with an average distance of 365 bp 
(maximum ~1.5kb) from their transcription start sites.
PP skin samples were defined as skin biopsies collected from the site of an active psoriatic 
lesion. Conversely, PN skin samples were biopsies collected from skin that showed no 
evidence of macroscopic change. All psoriasis patient samples were collected at least 4 
weeks after discontinuation of all systemic or topical therapy. Psoriasis Area and Severity 
Index (PASI) scores for psoriasis patients generally ranged from >10% to 30%. NN skin 
biopsies were defined as those biopsies collected from healthy volunteers with no clinically 
evident skin lesions and no self reported history of psoriatic outbreaks. Our study included 
12 PP, 8 PN and 10 NN skin samples. The PN samples were derived from donors who also 
contributed a PP sample; hence there were 8 “paired” PP/PN samples and 4 additional PP 
samples without a matched PN sample.
The workflow used for analysis of the methylation data is presented in Supplementary 
Figure 1. For each CpG target on each array we calculated both percent methylation (β-
value) and a methylation log-ratio (M-value; Methods; Figs S1 and S2). The M-values were 
used for tests of differential methylation since their standard deviations are more stable 
across a range of mean intensities than those of β –values (Supplementary Figure S3) (Du et 
al., 2010).
We defined a CpG as differentially methylated if it had a false-discovery rate (FDR) 
corrected p-value less than our significance threshold of 0.05 (Figure S1). CpG methylation 
in PP versus NN skin differed at 1,108 CpG sites, 88 of which demonstrated a greater than 
2-fold change in M-value (Fig 1; Supplementary Table ST1). The top differentially 
methylated sites for this comparison are shown in Table 1. A total of 27 CpG sites 
demonstrated differential methylation in PP skin compared to PN skin from the same 
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individual and 2 of those sites had a greater than 2-fold change in M-value (Fig 1; 
Supplementary Table ST2). Interestingly, PN skin compared to NN skin was differentially 
methylated at 15 CpGs, 8 of which had a greater than 2-fold change in M-value (Fig 1; 
Supplementary Table ST3). Additional loci may be discovered in follow-up studies with 
more samples in each group (Figure S4).
A total of 96 genes had at least two CpG sites in their vicinity where methylation levels were 
significant in the PP versus NN comparisons. CCND1 and GATA4 had 4 significant sites 
each, while GPX3 and SFRP4 had 3 significant sites each. The most extreme change was 
found in cg16139316, which lies upstream from S100A9 (p-value < 0.00001) within the 
epidermal differentiation complex (EDC), a region key to epidermal development (Volz et 
al., 1993). For this CpG site, methylation levels were 6.97 fold decreased in PP versus NN 
skin. S100A9 is strongly up-regulated in psoriatic skin (Benoit et al., 2006; Broome et al., 
2003; Semprini et al., 2002; Suarez-Farinas et al., 2010; Zhou et al., 2003) and the 
decreased methylation in psoriatic skin is consistent with its enhanced expression. In total, 
there were twelve CpG sites from the EDC whose methylation levels was decreased in PP 
versus NN and which mapped close to genes upregulated in psoriasis (S100A3, S100A5, 
S100A7, S100A12, SMCP, SPRR2A, SPRR2D, SPRR2E, LCE3A; Figure 2a).
The largest number of methylation differences and the differences of the largest magnitude 
were seen in the PP versus NN comparison (Supplementary Table ST1). There were 
comparatively few methylation changes in PP versus PN. These data contrast with 
expression analyses, where the PP versus PN skin comparisons are similar to the PP versus 
NN comparisons, though this may be an effect of small sample size (Gudjonsson et al., 
2010; Zhou et al., 2003). The largest fold methylation increase in PP vs. PN skin was in sites 
upstream from MCF.2 cell line derived transforming sequence-like (MCF2L; FC = 2.40) 
and laminin alpha 4 (LAMA4; FC = 2.58). The largest fold decreases were in sites upstream 
from synaptopodin (SYNPO; FC = -1.91) and bone marrow stromal cell antigen 2 precursor 
(BST2; FC = -1.76). While the changes in methylation were significant, none of these genes 
have demonstrated differential expression in psoriasis.
Methylation differences in PN compared to NN skin were similarly few in number. The 
greatest fold changes (≥ 2) were all increases in methylation in PN versus NN skin. These 
included sites near GALR1, ZNF454, ZNF540, NEF3, RGS7, MLF1, FLJ42486 and NRIP2 
(Supplementary Table ST3). MLF1 transcripts are down-regulated in psoriasis, consistent 
with the increase in methylation (Suarez-Farinas et al., 2010), but none of the other genes 
have been described as differentially expressed in psoriatic skin to our knowledge. The 
greatest decrease in methylation (−1.81 fold) was in a CpG site approximately 500bp 
upstream of the ZDHHC12 promoter.
Methylation levels correctly classify involved, uninvolved, and normal skin samples
We hypothesized that methylation levels of differentially methylated CpG sites could be 
used to classify the different skin groups. We performed between group analyses with 
principal component metrics and identified a subset of 50 sites (25 with increased 
methylation, 25 with decreased methylation) that differentiated PP from NN skin 
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(Supplementary Table ST4). Data on an additional seven PP samples was obtained for cross-
validation of clustering validity.
A heat-map of normalized M-values at the top 50 differentiating sites was generated with all 
PP, PN and NN samples (Figure 2b). The hierarchical clustering of these sites demonstrated 
excellent classifying power (Supplementary Table ST5). Classifications of psoriatic (PP or 
PN) versus NN were 100% accurate and 100% specific. PP clustered separately from both 
PN and NN skin, and performed well, with 100% sensitivity and 90% specificity. PN was 
classified with 75% sensitivity and 100% specificity. The lower sensitivity for PN samples 
was due to two PN samples (PN4, PN5) being classified as PP. Based on this dataset the 
classifying power of the global methylation data performed very well, especially at the 
classification of psoriatic versus normal, and may be as good a predictor of psoriasis as gene 
expression values.
Uninvolved skin exhibits intermediate levels of differential CpG methylation
We prepared box-plots of the top 50 sites, separated by the direction of the methylation 
change observed in PP versus NN skin and by sample group. The medians of the three 
groups for sites with increased and decreased methylation were significantly different by the 
Kruskal-Wallis rank sum test. The trend is apparent for both the raw β-values and the 
normalized M-values (Supplementary Table ST4). We also observed that PN skin had a 
methylation level intermediate to that of the NN and PP skin for these top 50 sites (Figure 
3). These intermediate methylation levels contrast with the expression levels of mRNA 
transcripts in PN skin which for many transcripts are usually very similar to that of normal 
skin (Bowcock et al., 2001). These differences may indicate intrinsic epigenetic differences 
in PN versus NN skin that may be reflective of a predisposition to psoriasis. However, the 
smaller differences in CpG methylation of PP vs. PN skin suggest that the number of 
samples available might have been too low (under-powered) to detect some of these 
alterations.
Correlation of methylation with gene expression
Nine PP, five PN, and six NN samples used for methylation analysis had also been used for 
global transcriptome analysis with the Affymetrix U95 arrays (Zhou et al., 2003). We were 
therefore able to perform a direct correlation between methylation at specific CpG loci and 
the level of expression of a downstream gene for these samples.
Correlations between methylation score values and gene expression levels were performed 
with R, and p-values were reported based on an FDR corrected p-value cutoff of 0.05. There 
were 12 CpG sites where methylation levels correlated significantly with gene expression 
levels at a nearby locus (adj. p-value ≤ 0.05; Supplementary Table ST6). Among these sites, 
9 demonstrated negative correlations with nearby genes: C10orf99, OAS2 (3 sites), 
LGALS3BP, KYNU, IL1B, TRIM22, and PHYHIP. Three demonstrated positive 
correlations with nearby genes: GDPD3, TRIM14, and CCND1. Many of the genes that 
demonstrated a negative correlation between expression and methylation are highly up-
regulated in psoriasis (C10orf99, OAS2, LGALS3BP, KYNU, IL1B, TRIM22; (Zhou et al., 
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2003), providing evidence of underlying methylation changes in the highly up-regulated 
genes in PP skin.
Overall, relatively few genes showed correlation between methylation status and gene 
expression. There are two possibilities for this. Firstly, the expression data used from 
previous generation expression arrays had fewer elements, covered fewer genes, and had 
less dynamic range than most modern arrays. A second reason may be low sample sizes (PP, 
n=9; PN, n=5; NN, n=6) which might have contributed to a lack of power to detect 
expression/methylation correlations. Therefore rather than directly correlating expression 
and methylation for the same samples we pursued a separate approach: A consensus list of 
890 down-regulated and 732 up-regulated genes in psoriatic skin determined across 
expression studies was recently described (Suarez-Farinas et al., 2010). When this list was 
intersected with our methylation data, 128 differentially methylated CpG sites in PP 
compared to NN were less than 1.5 kilobases from the transcription start site of 113 genes in 
that consensus list (Supplementary Tables 1–3). For example, the genes CCL27, DDAH2, 
TNS1 and TRIM2 all showed consistent down-regulation in psoriatic skin and we found 
consistently increased methylation in and near these genes. By contrast, IFI27, KYNU, 
OAS2, S100A9, SERPINB3 and TNIP3 all showed significantly increased expression in 
psoriasis, and we found significantly decreased methylation for sites near them. There was 
only one gene in the consensus set where decreased expression correlated with decreased 
methylation: FCGBP is significantly down-regulated in psoriatic lesions, but we found 
significantly decreased CpG methylation approximately 430bp upstream of this gene at 
cg19103704.
Fine mapping of differential methylation by pyrosequencing and response to treatment 
with a TNFα inhibitor
We targeted three regions for further methylation analyses. Each of these had exhibited a 
difference in CpG methylation in PP skin compared to NN skin (C10orf99 = −1.35; IFI27 = 
−2.74; SERPINB4 = −1.44). We used pyrosequencing as a separate approach to confirm 
these methylation differences and to investigate additional CpG sites within the c10orf99 
and IFI27 intervals. In all cases, the original CpG site determined to be differentially 
methylated with the Illumina bead array was included in the pyrosequencing assay, along 
with nearby CpG sites. For all of these loci, the NN and PN samples demonstrated greater 
methylation than was seen in the PP samples (Figure 4). Many of these differences were 
statistically significant. Hence, we confirmed the differential methylation between PP and 
NN and/or PN skin detected by methylation bead arrays, and also showed that additional 
CpG sites in the differentially methylated regions exhibited similar methylation trends.
We also had access to PP skin biopsies from five psoriasis patients who were being treated 
with the anti-TNF-alpha monoclonal antibody adalimumab (Humira®). The standard dosing 
of 80 mg was applied by subcutaneous (SC) injection at week 0, 40 mg SC at week 1, and 
thereafter 40 mg SC every other week (Menter et al., 2008). Characteristics of the patients, 
including age, sex, and Psoriasis Area and Severity Index (PASI) score over time were 
ascertained for these patients (Supplemental Table ST7).
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We obtained skin biopsies from these patients before treatment and after one month of 
adalimumab (post-treatment). The pre-treatment biopsies were taken from within a psoriatic 
plaque, and the post-treatment biopsies were taken either adjacent to the original biopsy site, 
or from a resolving psoriatic plaque contra-lateral to the original biopsy site. Four out of five 
patients responded well to adalimumab treatment and achieved a greater than 75% 
improvement in PASI score (PASI-75) at 6 months (ST7). Pyrosequencing at the same loci 
described above was also performed on the pre- and post-treatment samples. At one month 
plaques had not completely resolved. However, at each locus we observed that the mean 
methylation levels of treated samples increased, becoming more similar to that of 
uninvolved skin, though the difference was only statistically significant at CpG1 of 
C10orf99 (Figure 4). This suggests that methylation assays at a discrete set of loci might be 
a useful way to predict treatment response early in treatment.
Discussion
To our knowledge global CpG methylation changes in psoriatic versus normal skin have not 
previously been reported. We observed extensive differences in global methylation in PP 
skin compared to NN. These observations are similar to those we and others have made 
following expression comparisons of the same skin types (Bowcock et al., 2001; 
Gudjonsson et al., 2010; Oestreicher et al., 2001; Suarez-Farinas et al., 2010; Suomela et 
al., 2004). We identified a subset of differentially methylated CpG sites that correlated 
significantly with the differential expression of nearby genes. Many of these genes are 
highly up-regulated in psoriasis and a number map to the EDC. Some of the highly up-
regulated genes, such as KYNU, OAS2, S100A12, and SERPINB3 are members of a set of 
genes whose high expression level differentiates psoriasis from other inflammatory skin 
diseases such as atopic dermatitis (Guttman-Yassky et al., 2009). Hence, altered CpG 
methylation near genes such as these is expected to be a good predictor of the psoriatic state. 
Many of the genes with the greatest methylation differences are expressed by keratinocytes. 
This is similar to the major alterations in mRNA levels from psoriatic versus normal skin 
(Bowcock et al., 2001; Gudjonsson et al., 2010; Mee et al., 2007; Nomura et al., 2003; 
Quekenborn-Trinquet et al., 2005; Suarez-Farinas et al., 2010; Zhou et al., 2003). Psoriatic 
blood has limited expression changes compared to blood from healthy controls (Lee et al., 
2009) and we would expect similar findings from an investigation of methylation alterations 
in this tissue
We also identified methylation differences between PP compared to PN skin as well as 
between PN compared to NN skin. However, the number of differentially methylated sites in 
the PP versus PN comparisons was not nearly as great as those identified in the PP versus 
NN comparisons. This contrasts with expression studies where PP vs. NN and PP vs. PN 
comparisons yield some of the greatest alterations in transcript levels. In fact, PN skin 
frequently exhibited methylation levels that were intermediate with respect to PP and NN 
skin. This might be due to tissue heterogeneity in PN skin, but this difference has not been 
seen with expression studies to our knowledge. This observation needs to be explored 
further.
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Although we observed correlations (primarily inverse relationships) between CpG 
methylation and expression of nearby genes, a significant number of differentially 
methylated CpG sites did not exhibit correlation with expression. This might be due to 
limited power based on the number of samples studied. Moreover, some differentially 
methylated genes might be expressed at low levels and have been missed by hybridization 
based microarray analysis. In these instances, non-hybridization strategies, such as RNA 
sequencing (RNA-Seq) may provide insight into less abundant transcripts in psoriasis. In 
other instances, these methylation differences might reflect altered methylation of noncoding 
RNAs, long range regulatory elements such as enhancers (Brideau et al., 2010; Hoivik et al., 
2011; Lujambio et al., 2010; Shore et al., 2010; Yoon et al., 2005), or even elements 
mediating intra-chromosomal effects (Sharp et al., 2010).
It is unclear at this stage if the epigenetic differences described here are secondary to the 
altered signaling pathways of psoriasis, or are a stable predisposing event within psoriatic 
skin. A precedence for altered methylation predisposing to activation of the immune system 
is reported for interleukin-2 where demethylation at a specific CpG site in its promoter is 
associated with its transcriptional upregulation in mouse and humans (Bird, 2003; Bruniquel 
and Schwartz, 2003). This demethylation induces recruitment of Oct-1, and changes in 
histone modifications. Oct-1 remains on the enhancer region in a stable manner and leads to 
a faster and stronger induction upon subsequent stimulation. Hence, altered DNA 
methylation acts as a memory of the regulatory event (Murayama et al., 2006) and it is 
possible that similar types of epigenetic memory exist in psoriatic skin.
Multiple clinical trials have demonstrated the efficacy of TNF blockade for the treatment of 
psoriasis (Menter et al., 2007; Menter et al., 2008). When we examined the effect of 
adalimumab (Sladden et al., 2005) on global CpG methylation we observed that after a 
month of treatment, methylation levels had changed in the direction seen uninvolved skin. 
Hence, although altered methylation in psoriatic versus normal skin is not unexpected, the 
fact that it can be a surrogate for gene expression together with the relative ease with which 
it can be assayed makes it attractive as a possible predictor for diagnosing the status of 
activity in psoriatic skin, particularly when RNA from samples is inaccessible. Likewise, 
treatment response and remissions may be predicted, offering the opportunity to discontinue 
therapy for periods of time with significant cost saving to the patient.
Materials and Methods
Skin biopsy samples
The study was conducted according to Declaration of Helsinki Principles. Three to six 
millimeter punch biopsies were obtained from the PP and PN skin of psoriasis patients and 
NN skin from healthy controls (Supplementary Table ST8). The transcriptomes of some of 
these samples were previously analyzed and are described elsewhere (Bowcock et al., 2001; 
Zhou et al., 2003). Skin biopsies were obtained from collaborating dermatologists at 
Washington University School of Medicine (Saint Louis, MO), Psoriasis clinic, Baylor 
Hospital (Dallas, TX) or from the University of California in San Francisco (CA). Informed 
written consent was obtained from all individuals who donated skin biopsies. Protocols for 
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obtaining patient biopsies were approved by Institutional Review Boards for the protection 
of human subjects.
DNA methylation profiling with Illumina bead arrays
Qiagen DNeasy Kits were used to isolate genomic DNA from skin biopsy samples 
according to the manufacturer's instructions. All samples were analyzed for DNA integrity, 
purity and concentration on a Nanodrop Spectrophotometer DN-100 (Nanodrop 
Techonologies). Bisulfite DNA conversion was by the EZ DNA methylation kit (Zymo 
Research) according to the manufacturer's recommendations (Bibikova et al., 2006). 
Bisulfite-converted genomic DNA was then interrogated with the Illumina Infinium 
HumanMethylation27 Beadchip, with the recommended protocols provided by the 
manufacturer. After hybridization, the arrays were imaged with a BeadArray Reader 
scanner. Image processing, intensity data extraction and analyses were conducted with the 
BeadArray Reader.
Differential Methylation Analysis
Non-normalized methylation data were analyzed with the R (v2.12.0) Bioconductor 
(Biobase v2.10.0) methylumi (v1.4.0) and lumi (v2.2.0) packages (Davis et al., 2010; Du et 
al., 2008; Gentleman et al., 2004; R Development Core Team, 2010). Supplementary Figure 
1 provides a description of the workflow used for statistical analyses. Color channel 
intensities within each array were quantile normalized with the ‘lumiMethyC’ function, and 
data were globally normalized between arrays with simple scaling normalization via the 
‘lumiMethyN’ function. In some tables we report β-values and M-values. β-values are 
intuitive, and M-values were used for statistical tests. Let the intensity of the methylated and 
unmethylated alleles be Imeth and Iunmeth, respectively.
Limma (v3.6.6) was used to fit linear models to each CpG (detection p-value ≤ 0.01 in at 
least one sample) (Smyth, 2005). Contrasts were defined for PP versus NN and PN versus 
NN. The log-odds of differential methylation were calculated for each CpG in each contrast 
with the ‘eBayes’ function.
Paired PP/PN samples were treated as paired samples. Linear models were fitted to only 
these samples, and the ‘eBayes’ function was used to calculate the moderated paired t-test. 
All p-values were adjusted for multiple tests with the false discovery rate method 
(Benjamini and Hochberg, 1995). Supplemental power calculations were performed in R 
2.12.0 (Champely, 2009).
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Selection of the top 50 group discriminating differentially methylated CpG sites
Between-group analysis was used to determine CpG sites that most differentiate PP from 
NN skin. Between-group analysis of PP vs. NN was performed using M-values for 
differentially methylated CpG sites with the ‘bga’ function of the MADE4 R package 
(Culhane et al., 2002; Culhane et al., 2005). The discriminating method used was principal 
components analysis. The sites were selected as the top 25 increased and top 25 decreased 
methylation sites on the first principal component axis. The top 50 sites were subsequently 
used to generate heatmaps showing the discriminatory power of these sites with Euclidean 
distance measures and complete hierarchical clustering. Heatmaps were generated with the 
Heatplus R package (v1.20.0) with a 50 color palette from the marray package maPalette 
function (v1.28.0).
Correlation with gene expression
Pearson correlations coefficients and their 95% confidence intervals were calculated to 
evaluate the strength of linear dependence between methylation at specific CpG loci and the 
level of expression of a downstream target. The FDR adjusted p-values were calculated to 
test the null hypothesis of zero correlation. All analyses were performed with R statistical 
programming language (v2.10.1).
Pyrosequencing
CpG methylation at and around sites flanking the statistically significant Illumina CpG loci 
were further validated by with pyrosequencing of bisulfite-treated DNA. This allowed us to 
quantify methylation at multiple CpG sites individually (Colella et al., 2003). Sample 
bisulfite treatment, PCR amplification, pyrosequencing, and extraction of percent 
methylation were performed at EpigenDx (Worcester, MA). Loci analyzed were promoter 
regions of IFI27, SERPINB4 and C10orf99 genes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Venn diagram of the CpG sites exhibiting differential methylation for each of three contrasts 
with a significance cutoff of 0.05 for the adjusted p-value. The contrasts are PP compared to 
PN (paired t-test), PP compared to NN and PN compared to NN. For each set the upper 
number is a count of the number of CpG sites with increased methylation, and the lower 
number is the count of CpG sites with decreased methylation. The total count of unique sites 
showing increased or decreased methylation in at least one comparison is shown at the 
bottom right.
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Figure 2. 
A. Differentially methylated CpGs that map to the epidermal differentiation complex (EDC). 
Genes of the EDC are critical to epidermal development. Twelve differentially methylated 
CpG sites in PP compared to NN map to this region of chromosome 1. Shown are these sites 
and the nearby genes with chromosome ideogram. The image was adapted from a postscript 
generated with the UCSC genome browser (Fujita et al., 2010).
B. Heatmap showing PP, PN, and NN samples clustered with the top 50 CpG sites that 
differentiate PP from NN skin. Image was generated with normalized M-values. Red values 
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indicate relatively increased methylation while green indicates relatively decreased 
expression.
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Figure 3. 
Boxplots of methylation levels in three sample groups Shown are two boxplots of 
normalized M-value versus sample group (NN, PN, PP). The upper panel shows the 
methylation levels for the top 25 CpG sites that show increased methylation, and the lower 
panel shows the top 25 CpG sites with decreased methylation. Displayed p-values were 
derived from the nonparametric Kruskal-Wallis test for equality of medians among groups. 
Dark lines represent the median of each group. The bottom and top borders of each box are 
defined by the first and third quartiles. Whiskers reach out to data points up to 1.5 times the 
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interquartile range above or below the appropriate quartile. Data points outside of that range 
are considered outliers and are represented by circles.
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Figure 4. 
Pyrosequencing data in PP, PN and NN skin biopsies at CpG sites near C10orf99 (a), 
SERPINB4 (b), and IFI27 (c). Methylation levels (%) with 95% confidence intervals are 
plotted for each CpG site by group. P-values were calculated with a two-sample t-test 
(unequal variance) or paired t-test as appropriate. Symbols: †, Infinium site; *, p-value < 
0.05.
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